Feasibility of Estimating the Prevalence and Management of Stage 4 CKD the Gard, France

Overview

The main objective of this study is to evaluate the feasibility of estimating the prevalence of stage 4 and 5 chronic kidney disease in the Gard department of France from data obtained via laboratory databases. To verifiy if the demand for care thus authenticated by laboratory tests is adapted to nephrology care delivery, as recommended by the French High Authority of Health (HAS), laboratory data will be compared with those of patients seen by nephrologists in the department.

Full Title of Study: “Feasibility Study on Estimating the Prevalence and Management of Stage 4 Chronic Kidney Disease in Adults Via Laboratories and Nephrologists in the Gard, France”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2025

Arms, Groups and Cohorts

  • The study population
    • Persons with stage >=4 chronic kidney disease.

Clinical Trial Outcome Measures

Primary Measures

  • The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (raw number)
    • Time Frame: from baseline (day 0) to 12 months
  • The prevalence of chronic kidney disease stage > = 4 in the Gard according to laboratory data (%)
    • Time Frame: from baseline (day 0) to 12 months

Secondary Measures

  • The percentage of patients with CKD stage >= 4 correctly reported by participating nephrologists
    • Time Frame: from baseline (day 0) to 12 months
  • For each nephrologist participating in the study, the % of patients with stage >=4 chronic kidney disease who are correctly declared
    • Time Frame: from baseline (day 0) to 12 months
  • The % of patients with chronic kidney disease stage > = 4 in the Gard according to laboratory data and who are not seen by a nephrologist
    • Time Frame: from baseline (day 0) to 12 months

Participating in This Clinical Trial

Inclusion Criteria

  • chronic kidney disease (stage >= 4) Exclusion Criteria:

-

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Centre Hospitalier Universitaire de Nīmes
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Olivier Moranne, MD, PhD, Study Director, Centre Hospitalier Universitaire de Nîmes
  • Overall Contact(s)
    • Olivier Moranne, MD, PhD, +33.(0)4.66.68.31.49, olivier.moranne@chu-nimes.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.